Ollin Biosciences
Latest round
- Series B
Last raised
- May 2026
Total raised
- $207M
Investors
- 10
About Ollin Biosciences
Based in the US, Ollin Biosciences, Inc.Ollin Biosciences, Inc. was founded in 2023 and is headquartered in Austin, US. The company is dedicated to creating therapies for ophthalmic conditions. In June 2026, Ollin Biosciences, Inc.Ollin Biosciences is focused on developing advanced therapies for serious ophthalmic diseases, primarily targeting conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and thyroid eye disease (TED). The company's core product offerings include OLN324, a higher potency, small format VEGF/Ang2 bispecific antibody designed for wet AMD and DME treatment, and OLN102, a first-in-class IGF-1R/TSHR bispecific antibody aimed at TED. These therapies work by targeting specific biological pathways associated with these conditions, aiming to improve vision preservation and enhance the quality of life for patients.Ollin Biosciences generates revenue through the development and commercialization of its therapeutic products, which are positioned for direct sales to healthcare providers and institutions involved in the treatment of ophthalmic conditions. The company’s transaction structure primarily operates on a B2B basis, with potential partnerships and collaborations being established with healthcare entities and pharmaceutical distributors. These relationships facilitate the distribution of Ollin's flagship products, specifically OLN324 and OLN102, to a diverse client base that includes hospitals, specialty clinics, and healthcare networks. As the products advance through clinical trials and regulatory approval phases, the company aims to establish pricing strategies that align with the value delivered through its innovative therapies, ensuring access to effective treatment options for patients suffering from vision-threatening diseases. The company is targeting the launch of new products designed for ophthalmic diseases, with a focus on expanding into international markets by 2026. This strategic utilization of funds aims to support the development of their innovative therapies and meet the growing demand in the ophthalmic treatment landscape.
Who invested in Ollin Biosciences
10 investors across 2 rounds
See all investors in Ollin Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ollin Biosciences
Who invested in Ollin Biosciences?
Ollin Biosciences has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ollin Biosciences raised?
Ollin Biosciences has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Ollin Biosciences last raise money?
Ollin Biosciences's most recent round on record is a Series B, in May 2026.
What does Ollin Biosciences do?
Based in the US, Ollin Biosciences, Inc.
Where is Ollin Biosciences headquartered?
Ollin Biosciences is headquartered in Austin, US.
Which VCs invest in companies like Ollin Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ollin Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Ollin Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.